专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

SG10202109691UA ANTI-PACAP ANTIBODIES AND USES THEREOF 未知
公开(公告)号：SG10202109691UA
公开(公告)日：2021-10-28
申请号：SG10202109691U
申请日：2017-04-14
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： LOOMIS MARIA-CRISTINA , GARCIA-MARTINEZ LEON , DUTZAR BENJAMIN , ALLISON DANIEL , HENDRIX KATHERINE , OJALA ETHAN , FAN PEI , SMITH JEFFREY , LATHAM JOHN , KARASEK CHARLIE , MULLIGAN JENNY , SCALLEY-KIM MICHELLE , STEWART ERICA , RUBIN VANESSA LISBETH , BILLGREN JENS J
摘要： The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

2. 发明专利

AU2013203851A1 Antagonists of IL-6 to raise albumin and/or lower CRP 未知
公开(公告)号：AU2013203851A1
公开(公告)日：2013-05-02
申请号：AU2013203851
申请日：2013-04-11
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： SMITH JEFFREY
IPC分类号： A61K39/395
摘要： Abstract The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

3. 发明专利

SG11201808630WA HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF 未知
公开(公告)号：SG11201808630WA
公开(公告)日：2018-10-30
申请号：SG11201808630W
申请日：2017-04-14
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： LOOMIS MARIA-CRISTINA , GARCIA-MARTINEZ LEON , DUTZAR BENJAMIN , ALLISON DANIEL , HENDRIX KATHERINE , OJALA ETHAN , FAN PEI , SMITH JEFFREY , LATHAM JOHN , KARASEK CHARLIE , MULLIGAN JENNY , SCALLEY-KIM MICHELLE , STEWART ERICA , RUBIN VANESSA LISBETH , BILLGREN JENS J
IPC分类号： C07K16/26 , A61K39/00 , C07K16/18 , C07K19/00
摘要： The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

4. 发明专利

CO6241159A2 ANTICUERPOS PARA IL-6 Y USO DE ESTOS 未知
公开(公告)号：CO6241159A2
公开(公告)日：2011-01-20
申请号：CO09141956
申请日：2009-12-11
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： GARCIA-MARTINEZ LEON , JENSEN ANNE ELISABETH , SMITH JEFFREY , KOVACEVICH BRIAN , LATHAM JOHN , OJALA ETHAN , DUTZAR BEN , OLSON KATIE
IPC分类号： C07K16/24
摘要： La presente invención se dirige a anticuerpos y fragmentos de los mismos que tienen especificidad enlazante para IL-6. Otra implementación de esta invención se relaciona con los anticuerpos descritos en este documento, y fragmentos enlazantes de los mismos, que comprenden las secuencias de polipéptidos VH, VL y CDR descritos en este documento, y los polínucleótidos que los codifican. La invención también contempla conjugados de anticuerpos anti-IL-6 y fragmentos enlazantes de los mismos conjugados a una o más de las mitades funcionales o detectables. La invención contempla también métodos para hacer los mencionados anticuerpos anti-IL-6 y los fragmentos enlazantes de los mismos. Las implementaciones de la invención también se relacionan con el uso de los anticuerpos anti-IL-6, y fragmentos enlazantes de los mismos, para el diagnóstico, evaluación y tratamiento de enfermedades y desórdenes asociados con la IL-6. Estos anticuerpos pueden enlazar al menos una de las lL-6 soluble, IL-6 expresada en la superficie celular, IL-6/IL-6R y/o prevenir la asociación de lL-6 e IL-6R, la asociación de IL-6/lL-6R y gp 130 y o la formación de multímeros IL-6/lL-6R/gp 130 y, por lo tanto, inhibir un efecto biológico asociado con cualquiera de los anteriormente citados. 1.- Un anticuerpo anti-humano lL-6 o un fragmento de anticuerpo que específicamente enlaza al(los) mismo(s) epítope(s) lineal(es) o conformacional(es) y/o que compiten para el enlazamiento al(los) mismo(s) epítope(s) lineal(es) o conformacional(es) en un polipéptido humano IL-6 intacto o un fragmento de éste como un anticuerpo anti-humano IL-6 seleccionado del grupo que consiste de Ab1, Ab2, Ab3, Ab4, Ab5, Ab6, Ab7, Ab8, Ab9, Ab10, Ab11, Ab12, Ab13, Ab14, Ab15, Ab16, Ab17, Ab18, Ab19, Ab20, Ab21, Ab22, Ab23, Ab24, Ab25, Ab26, Ab27, Ab28, Ab29, Ab30, Ab31, Ab32, Ab33, Ab34, Ab35 y Ab36.

5. 发明专利

SG11201808632YA ANTI-PACAP ANTIBODIES AND USES THEREOF 未知
公开(公告)号：SG11201808632YA
公开(公告)日：2018-10-30
申请号：SG11201808632Y
申请日：2017-04-14
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： LOOMIS MARIA-CRISTINA , GARCIA-MARTINEZ LEON , DUTZAR BENJAMIN , ALLISON DANIEL , HENDRIX KATHERINE , OJALA ETHAN , FAN PEI , SMITH JEFFREY , LATHAM JOHN , KARASEK CHARLIE , MULLIGAN JENNY , SCALLEY-KIM MICHELLE , STEWART ERICA , RUBIN VANESSA LISBETH , BILLGREN JENS J
IPC分类号： A61K39/00 , A61K38/00 , A61K39/395 , C12P21/08
摘要： The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

6. 发明专利

SG10202109689QA HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF 未知
公开(公告)号：SG10202109689QA
公开(公告)日：2021-10-28
申请号：SG10202109689Q
申请日：2017-04-14
申请人： ALDER BIOPHARMACEUTICALS INC
发明人： LOOMIS MARIA-CRISTINA , GARCIA-MARTINEZ LEON , DUTZAR BENJAMIN , ALLISON DANIEL , HENDRIX KATHERINE , OJALA ETHAN , FAN PEI , SMITH JEFFREY , LATHAM JOHN , KARASEK CHARLIE , MULLIGAN JENNY , SCALLEY-KIM MICHELLE , STEWART ERICA , RUBIN VANESSA LISBETH , BILLGREN JENS J
摘要： The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式